← Back to all trials
Recruiting
NCT07851220
A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy
Conditions: Glomerulonephritis, Membranous
Sex: All
Ages: 18 Years – 79 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 159
Sponsor: Amgen
Location: Academic Medical Research Institute Los Angeles California
Summary
The primary objective of this study to evaluate the efficacy of inebilizumab on primary membranous nephropathy (PMN) disease activity as measured by complete remission in participants with PMN.
Eligibility Criteria
Inclusion Criteria:
* Adults aged ≥18 years and \
Source: ClinicalTrials.gov (NCT07851220). StuddyBuddy aggregates publicly available trial information.
